Local view for "http://purl.org/linkedpolitics/eu/plenary/2005-10-25-Speech-2-051"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20051025.4.2-051"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spokenAs | |
| lpv:translated text |
"Commissioner, thank you for your introduction. I am still left with three questions about avian flu. Last week, you communicated that you would advise Member States to have people who work in the poultry sector vaccinated with the flu vaccine. Whilst this is in itself a useful measure, because that way, it is possible to reduce the risk of mutation of H5N1 into a form that is transmitted from one human being to another, what causes me anxiety, though, is the excessively non-committal tone of a suggestion to Member States that they might make a recommendation to poultry farmers.
I think that the European Union should learn from the previous health crises with SARS and BSE. In both cases, the Member States adopted their own policies, sometimes with opposite effects. My first question is whether the Commission can shed light on this as quickly as possible. I would also like to hear from the Commission what priority it gives to support for flu vaccination campaigns in the poultry sector in Turkey and Romania and what support is in place for similar vaccination campaigns in Asia.
My second question concerns the availability of medicines. According to experts, EUR 150 million would be sufficient for the preliminary development of new medicines to stave off the pandemic. Which products exactly will you be making available?
My third and final question has to do with the capacity for producing medicines and their affordability. Are you prepared, in the event of a pandemic, to suspend the relevant patent rights and data exclusivity?"@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples